These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Meningitis caused by Pseudomonas aeruginosa. Treatment with meropenem]. Barberán J; García MC; Campos A; Khorrami S Enferm Infecc Microbiol Clin; 1998 May; 16(5):249. PubMed ID: 9666592 [No Abstract] [Full Text] [Related]
3. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group. Klugman KP; Dagan R Antimicrob Agents Chemother; 1995 May; 39(5):1140-6. PubMed ID: 7625802 [TBL] [Abstract][Full Text] [Related]
4. Meropenem, a new carbapenem antibiotic. Fish DN; Singletary TJ Pharmacotherapy; 1997; 17(4):644-69. PubMed ID: 9250544 [TBL] [Abstract][Full Text] [Related]
5. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group. Schmutzhard E; Williams KJ; Vukmirovits G; Chmelik V; Pfausler B; Featherstone A J Antimicrob Chemother; 1995 Jul; 36 Suppl A():85-97. PubMed ID: 8543502 [TBL] [Abstract][Full Text] [Related]
6. Laboratory data which differentiate meropenem and imipenem. Edwards JR; Turner PJ Scand J Infect Dis Suppl; 1995; 96():5-10. PubMed ID: 7652504 [TBL] [Abstract][Full Text] [Related]
7. Carbapenems: monotherapy in intra-abdominal sepsis. Wilson SE Scand J Infect Dis Suppl; 1995; 96():28-33. PubMed ID: 7652500 [TBL] [Abstract][Full Text] [Related]
8. Carbapenems: a potent class of antibiotics. Nicolau DP Expert Opin Pharmacother; 2008 Jan; 9(1):23-37. PubMed ID: 18076336 [TBL] [Abstract][Full Text] [Related]
9. Carbapenems in serious infections: a risk-benefit assessment. Norrby SR Drug Saf; 2000 Mar; 22(3):191-4. PubMed ID: 10738843 [TBL] [Abstract][Full Text] [Related]
10. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients. Kuo BI; Fung CP; Liu CY Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445 [TBL] [Abstract][Full Text] [Related]
11. Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections. Mohr JF Clin Infect Dis; 2008 Sep; 47 Suppl 1():S41-51. PubMed ID: 18713049 [TBL] [Abstract][Full Text] [Related]
12. Strategies and new developments in the management of bacterial meningitis. Miranda J; Tunkel AR Infect Dis Clin North Am; 2009 Dec; 23(4):925-43, viii-ix. PubMed ID: 19909891 [TBL] [Abstract][Full Text] [Related]
13. Long-Term outcome of neonatal Citrobacter koseri (diversus) meningitis treated with imipenem/meropenem and surgical drainage. Straussberg R; Harel L; Amir J Infection; 2001 Oct; 29(5):280-2. PubMed ID: 11688908 [TBL] [Abstract][Full Text] [Related]
14. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group. Odio CM; Puig JR; Feris JM; Khan WN; Rodriguez WJ; McCracken GH; Bradley JS Pediatr Infect Dis J; 1999 Jul; 18(7):581-90. PubMed ID: 10440432 [TBL] [Abstract][Full Text] [Related]